Taysha Gene Therapies, Inc. — Cash Flow Charts
8 quarters of history · ending 2025-12-31 · SEC EDGAR
Source:10-K · 10-Q
Capital Allocation
How management deploys cash: investing in the business (Capex + M&A) vs returning to shareholders (Buybacks + Dividends).
Capital Allocation Waterfall
Buybacks vs Stock-Based Comp
Cash Flow
Cash Flow by Activity
Operating Cash Flow↓-11.2% -$2M
$-22M
Free Cash Flow
$-250K
Investing Cash Flow
$62K
Financing Cash Flow
$50M
Capex
$250K
Stock-Based Comp↑+9.7% +$313K
$4M
D&A↓-1.6% -$5K
$299K
SBC Allocated Expense↑+9.7% +$313K
$4M